Is Yasmin as Safe as Other Contraceptive Pills?

Thorneycroft IH . Yasmin: the reason why. Eur J Contracept Reprod Health Care 2000;(Suppl 3):13-13.

Aznar J , Mira Y , Vayá A . Anticonceptivos orales y riesgo tromboembólico. Haematologica 2000;(Suppl 2):208-208.

Rosendaal F , Helmerhorst F , Vanderbroucke J . Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002;22:201-201.

Aznar J , Vayá A , Estellés A , et al. Risk of venous thrombosis in carriers of the prothrombin G20210 A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000;85:1271-1271.

Weiss G . Risk of venous thromboembolism with third generation oral contraceptives: A review. Am J Obstet Gynecol 1999;180:295-295.

Sheldon T . Dutch GPs warned against new contraceptive pill. BMJ 2002;324:869-869.

Yuzpe AA . Oral contraception: Trends over time. J Reprod Med 2002;47(Suppl 11):967-967.

Vayá A , Mira Y , Ferrando F , et al. Transient ischaemic attack associated with the new contraceptive Yasmin. Thromb Res 2003;112:21-21.

Koning R , Cribier A , Gerber L , et al. A new treatment for severe pulmonary embolism. Percutaneous rheolytic thrombectomy. Circulation 1997;96:2498-2498.

Vayá A , Mira Y , Mateo J , et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003;89: 452-452.

Medicines Evaluation Board . Statement on Yasmin and VTE risk. Available in Dutch at: http://www.cbg-meb.nl/ under Nieuws en Publicities, 28 March 2002. Accessed May 2003.